Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials | Zendy

Tejas Patel | Zendy; Parvati B. Patel | Zendy; Manish Barvaliya | Zendy; Manoj Kumar Saurabh | Zendy; Hira Lal Bhalla | Zendy; Prem Parkash Khosla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials

Author(s) -

Tejas Patel,

Parvati B. Patel,

Manish Barvaliya,

Manoj Kumar Saurabh,

Hira Lal Bhalla,

Prem Parkash Khosla

Publication year - 2021

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2021.03.015

Subject(s) - lopinavir , ritonavir , medicine , lopinavir/ritonavir , adverse effect , randomized controlled trial , relative risk , ribavirin , virology , confidence interval , covid-19 , viral load , disease , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , infectious disease (medical specialty) , hepatitis c virus

Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research